A Phase 1 interventional study of Ramucirumab (IMC-1121B ) and Paclitaxel in Adenocarcinoma, sponsored by Eli Lilly and Company. Completed at 3 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-06-18.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Adenocarcinoma with a site in Japan — 11 open to participants now, 18 under way, 7 of them phase 3. Adenocarcinoma · Japan.
Among the 33 studies in Adenocarcinoma with a site in Japan, this one is the 32nd largest by enrollment, is one of 3 that started in 2010, is one of 9 in phase 1, and was the 4th registered.
620 studies on the registry are indexed under Adenocarcinoma; 148 are open to participants now.
Browse Adenocarcinoma studies →11 of the 33 studies in Adenocarcinoma with a site in Japan are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Japan, Australia
Ages 18+
Astellas Pharma Global Development, Inc. · Sites in Japan, United States, China and 1 more country
Ages 18+
National Cancer Center, Japan · Sites in Japan, Korea, Republic of
Ages 18–80
Astellas Pharma Global Development, Inc. · Sites in Japan, United States
Ages 18+
AstraZeneca · Sites in Japan, United States, Australia and 21 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 111 Adenocarcinoma studies recruiting now, 82 (74%) set no upper age limit and 11 (10%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 9 · Phase 3 15
First in 2009; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 57 across 490 interventional studies indexed under Adenocarcinoma.
Median enrollment 250 across the 33 interventional studies. Of the 13 that completed or were terminated, 8 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 33 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 7 studies filed under Adenocarcinoma — fewer than ten, so there is no comparison to draw.
3 of the studies in Adenocarcinoma with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04379596AstraZenecaPh1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | 2027-05-04 |
| NCT06561685Eli Lilly and CompanyA Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors | 2027-10 |
| NCT06038578Toray Industries, IncA Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer | 2027-10-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 33 studies in Adenocarcinoma with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Investigate the safety and tolerability of ramucirumab (IMC-1121B) drug product (DP) in combination with paclitaxel.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each treatment cycle is 4 weeks (28 days)
Biological: Ramucirumab (IMC-1121B ) · Drug: Paclitaxel
8 milligrams/kilogram (mg/kg) intravenously on Days 1 and 15 of each 28-ay cycle
Also known as: LY3009806, IMC-1121B
80 milligram/square meter (mg/m2) intravenously Days 1, 8, and 15 of each 28 day cycle
Number of Participants With a Dose-Limiting Toxicity (DLT) During Cycle 1
DLT based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCICTCAE v4.02) in Cycle (Cy) 1 due to study drug (SD) with (w/): Grade (Gr) ≥3 neutropenia w/fever ≥38.5°C or w/bacteremia or sepsis, thrombocytopenia w/bleeding and platelet substitution, prothrombin and/or partial thromboplastin time w/no anticoagulation, hyperbilirubinemia; Gr 4: neutropenia \>5 days, thrombocytopenia, Gr 4 or uncontrollable hypertension QTc\>500 milliseconds (ms) or increase ≥100 ms increase in 24 hours after SD or significant arrhythmia in this period; Gr ≥3 nonhematologic toxicity (tox), excluding Gr 3 hypersensitivity, hypertension, injection-site reaction, arthralgia/myalgia, asthenia/fatigue, diarrhea w/out loperamide/nausea/vomiting w/out antiemetic and transient aminotransferase elevation. SD tox=delay \>1 week in ramucirumab (RAM) dose or omission of 1 dose of RAM or 2 paclitaxel doses due to tox in Cy 1 or delay \>2 weeks between Cy 1 and Cy 2 due to persistent tox.
Time frame: Cycle 1 of 28-day cycle
Number of Participants With Adverse Events (AEs)
The number of participants who experienced AEs of any grade, AEs of Grade ≥3 or AEs resulting in death that were considered to be related to ramucirumab \[RAM (IMC-1121B)\] or paclitaxel (PAC). A summary of serious adverse events (SAEs) and all other non-SAEs, regardless of causality, is located in the Reported Adverse Events module.
Time frame: Up to 47 weeks post baseline
Number of Participants With Serious Adverse Events (SAEs)
The number of participants who experienced SAEs that were considered to be related to ramucirumab \[RAM (IMC-1121B)\] or paclitaxel (PAC). A summary of SAEs and all other non-SAEs, regardless of causality, is located in the Reported Adverse Events module.
Time frame: Up to 47 weeks post baseline
Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 1
Cmax after a single dose of ramucirumab (IMC-1121B).
Time frame: Cycle 1 Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
Serum Anti-Ramucirumab Antibody Assessment (Immunogenicity)
The percentage of participants who were treatment-emergent positive for anti-ramucirumab (IMC-1121B) antibodies.
Time frame: Cycle 1 through Cycle 5 (28-day cycles)
Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 1
AUC from time 0 to infinity (0-∞) after a single dose of ramucirumab (IMC-1121B).
Time frame: Cycle 1 Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
Ramucirumab Half-Life (t1/2) for Cycle 1
Terminal t1/2 (the time it takes for the concentration of ramucirumab (IMC-1121B) in plasma or serum to decline by 50%) after a single dose of ramucirumab (IMC-1121B).
Time frame: Cycle 1: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
Ramucirumab Clearance (CL) or Cycle 1
CL \[the volume of plasma or serum cleared of ramucirumab (IMC-1121B) per unit time\] after a single dose of ramucirumab (IMC-1121B).
Time frame: Cycle 1: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 1
Vss \[distribution of ramucirumab (IMC-1121B) in the body at steady state\] after a single dose of ramucirumab (IMC-1121B).
Time frame: Cycle 1: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 2
Cmax after multiple doses of ramucirumab (IMC-1121B).
Time frame: Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 2
AUC within the dosing interval (0-τ) after multiple doses of ramucirumab (IMC-1121B).
Time frame: Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
Ramucirumab Half-Life (t1/2) for Cycle 2
Terminal t1/2 \[the time it takes for the concentration of ramucirumab (IMC-1121B) in plasma or serum to decline by 50%\] after multiple doses of ramucirumab(IMC-1121B).
Time frame: Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
Ramucirumab Clearance (CL) for Cycle 2
CL \[the volume of plasma or serum cleared of ramucirumab (IMC-1121B) per unit time\] at steady state after multiple doses of ramucirumab (IMC-1121B).
Time frame: Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 2
Vss \[distribution of ramucirumab (IMC-1121B) in in the body at steady state\] is not calculated for multiple doses of ramucirumab (IMC-1121B).
Time frame: Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 3
Due to sparse pharmacokinetic sampling ramucirumab (IMC-1121B) Cmax could not be calculated in Cycle 3.
Time frame: Cycle 3: Pre-infusion, Day 1 of 28-day cycle
Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 3
Due to the sparse pharmacokinetic sampling ramucirumab (IMC-1121B) AUC within the dosing interval (0-τ) could not be calculated in Cycle 3.
Time frame: Cycle 3: Pre-infusion, Day 1 of 28-day cycle
Ramucirumab Half-Life (t 1/2) for Cycle 3
Due to sparse pharmacokinetic sampling ramucirumab (IMC-1121B) t1/2 could not be calculated in Cycle 3.
Time frame: Cycle 3: Pre-infusion, Day 1 of 28-day cycle
Ramucirumab Clearance (CL) for Cycle 3
Due to sparse pharmacokinetic sampling CL could not be calculated for ramucirumab (IMC-1121B) in Cycle 3.
Time frame: Cycle 3: Pre-infusion, Day 1 of 28-day cycle
Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 3
Due to sparse pharmacokinetic sampling Vss for ramucirumab (IMC-1121B) could not be calculated in Cycle 3.
Time frame: Cycle 3: Pre-infusion, Day 1 of 28-day cycle
Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 4
Due to sparse pharmacokinetic sampling ramucirumab (IMC-1121B) Cmax could not be calculated in Cycle 4.
Time frame: Cycle 4: Pre-infusion, Day 1 of 28-day cycle
Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 4
Due to sparse pharmacokinetic sampling AUC within the dosing interval (0-τ) for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.
Time frame: Cycle 4: Pre-infusion, Day 1 of 28-day cycle
Ramucirumab Half-Life (t 1/2) for Cycle 4
Due to sparse pharmacokinetic sampling t1/2 for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.
Time frame: Cycle 4: Pre-infusion, Day 1 of 28-day cycle
Ramucirumab Clearance (CL) for Cycle 4
Due to sparse pharmacokinetic sampling CL for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.
Time frame: Cycle 4: Pre-infusion, Day 1 of 28-day cycle
Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 4
Due to sparse pharmacokinetic sampling Vss for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.
Time frame: Cycle 4: Pre-infusion, Day 1 of 28-day cycle
| Milestone | Ramucirumab + Paclitaxel |
|---|---|
| Started | 6 |
| Received any quantity of study drug | 6 |
| Completed | 6 |
| Not completed | 0 |
DLT based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCICTCAE v4.02) in Cycle (Cy) 1 due to study drug (SD) with (w/): Grade (Gr) ≥3 neutropenia w/fever ≥38.5°C or w/bacteremia or sepsis, thrombocytopenia w/bleeding and platelet substitution, prothrombin and/or partial thromboplastin time w/no anticoagulation, hyperbilirubinemia; Gr 4: neutropenia \>5 days, thrombocytopenia, Gr 4 or uncontrollable hypertension QTc\>500 milliseconds (ms) or increase ≥100 ms increase in 24 hours after SD or significant arrhythmia in this period; Gr ≥3 nonhematologic toxicity (tox), excluding Gr 3 hypersensitivity, hypertension, injection-site reaction, arthralgia/myalgia, asthenia/fatigue, diarrhea w/out loperamide/nausea/vomiting w/out antiemetic and transient aminotransferase elevation. SD tox=delay \>1 week in ramucirumab (RAM) dose or omission of 1 dose of RAM or 2 paclitaxel doses due to tox in Cy 1 or delay \>2 weeks between Cy 1 and Cy 2 due to persistent tox.
| participants | Ramucirumab + Paclitaxel |
|---|---|
| Number of Participants With a Dose-Limiting Toxicity (DLT) During Cycle 1 | 0 |
The number of participants who experienced AEs of any grade, AEs of Grade ≥3 or AEs resulting in death that were considered to be related to ramucirumab \[RAM (IMC-1121B)\] or paclitaxel (PAC). A summary of serious adverse events (SAEs) and all other non-SAEs, regardless of causality, is located in the Reported Adverse Events module.
| participants | Ramucirumab + Paclitaxel |
|---|---|
| RAM-Related AEs Any Grade | 6 |
| PAC-Related AEs Any Grade | 6 |
| RAM-Related AEs Any Grade ≥3 | 2 |
| PAC-Related AEs Any Grade ≥3 | 4 |
| RAM-Related AEs Resulting in Death | 0 |
| PAC-Related AEs Resulting in Death | 0 |
The number of participants who experienced SAEs that were considered to be related to ramucirumab \[RAM (IMC-1121B)\] or paclitaxel (PAC). A summary of SAEs and all other non-SAEs, regardless of causality, is located in the Reported Adverse Events module.
| participants | Ramucirumab + Paclitaxel |
|---|---|
| RAM-Related SAEs | 2 |
| PAC-Related SAEs | 2 |
Cmax after a single dose of ramucirumab (IMC-1121B).
| micrograms/milliliter (µg/mL) | Ramucirumab + Paclitaxel |
|---|---|
| Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 1 | 176 ± 46.6 |
The percentage of participants who were treatment-emergent positive for anti-ramucirumab (IMC-1121B) antibodies.
| percentage of participants | Ramucirumab + Paclitaxel |
|---|---|
| Serum Anti-Ramucirumab Antibody Assessment (Immunogenicity) | 0 |
AUC from time 0 to infinity (0-∞) after a single dose of ramucirumab (IMC-1121B).
| micrograms*hour/milliliter (µg*h/mL) | Ramucirumab + Paclitaxel |
|---|---|
| Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 1 | 34100 ± NA |
Terminal t1/2 (the time it takes for the concentration of ramucirumab (IMC-1121B) in plasma or serum to decline by 50%) after a single dose of ramucirumab (IMC-1121B).
| hours (h) | Ramucirumab + Paclitaxel |
|---|---|
| Ramucirumab Half-Life (t1/2) for Cycle 1 | 190 (138 to 225) |
CL \[the volume of plasma or serum cleared of ramucirumab (IMC-1121B) per unit time\] after a single dose of ramucirumab (IMC-1121B).
| liters/hour (L/h) | Ramucirumab + Paclitaxel |
|---|---|
| Ramucirumab Clearance (CL) or Cycle 1 | 0.0166 ± NA |
Vss \[distribution of ramucirumab (IMC-1121B) in the body at steady state\] after a single dose of ramucirumab (IMC-1121B).
| liters (L) | Ramucirumab + Paclitaxel |
|---|---|
| Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 1 | 3.27 ± NA |
Cmax after multiple doses of ramucirumab (IMC-1121B).
| micrograms/milliliter (µg/mL) | Ramucirumab + Paclitaxel |
|---|---|
| Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 2 | 284 ± 39.7 |
AUC within the dosing interval (0-τ) after multiple doses of ramucirumab (IMC-1121B).
| micrograms*hour/milliliter (µg*h/mL) | Ramucirumab + Paclitaxel |
|---|---|
| Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 2 | 41900 ± 951 |
Terminal t1/2 \[the time it takes for the concentration of ramucirumab (IMC-1121B) in plasma or serum to decline by 50%\] after multiple doses of ramucirumab(IMC-1121B).
| hours (h) | Ramucirumab + Paclitaxel |
|---|---|
| Ramucirumab Half-Life (t1/2) for Cycle 2 | 218 (218 to 218) |
CL \[the volume of plasma or serum cleared of ramucirumab (IMC-1121B) per unit time\] at steady state after multiple doses of ramucirumab (IMC-1121B).
| liters/hour (L/h) | Ramucirumab + Paclitaxel |
|---|---|
| Ramucirumab Clearance (CL) for Cycle 2 | 0.0136 ± 0.000342 |
Vss \[distribution of ramucirumab (IMC-1121B) in in the body at steady state\] is not calculated for multiple doses of ramucirumab (IMC-1121B).
No measurements were reported for this outcome.
Due to sparse pharmacokinetic sampling ramucirumab (IMC-1121B) Cmax could not be calculated in Cycle 3.
No measurements were reported for this outcome.
Due to the sparse pharmacokinetic sampling ramucirumab (IMC-1121B) AUC within the dosing interval (0-τ) could not be calculated in Cycle 3.
No measurements were reported for this outcome.
Due to sparse pharmacokinetic sampling ramucirumab (IMC-1121B) t1/2 could not be calculated in Cycle 3.
No measurements were reported for this outcome.
Due to sparse pharmacokinetic sampling CL could not be calculated for ramucirumab (IMC-1121B) in Cycle 3.
No measurements were reported for this outcome.
Due to sparse pharmacokinetic sampling Vss for ramucirumab (IMC-1121B) could not be calculated in Cycle 3.
No measurements were reported for this outcome.
Due to sparse pharmacokinetic sampling ramucirumab (IMC-1121B) Cmax could not be calculated in Cycle 4.
No measurements were reported for this outcome.
Due to sparse pharmacokinetic sampling AUC within the dosing interval (0-τ) for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.
No measurements were reported for this outcome.
Due to sparse pharmacokinetic sampling t1/2 for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.
No measurements were reported for this outcome.
Due to sparse pharmacokinetic sampling CL for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.
No measurements were reported for this outcome.
Due to sparse pharmacokinetic sampling Vss for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ramucirumab + Paclitaxel | — | 4/6 (66.7%) | 6/6 (100%) |
| Event | Ramucirumab + Paclitaxel |
|---|---|
| PneumoniaInfections and infestations | 2/6 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/6 |
| Intestinal obstructionGastrointestinal disorders | 1/6 |
| Decreased appetiteMetabolism and nutrition disorders | 1/6 |
| Lymphangiosis carcinomatosaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/6 |
| MeningismNervous system disorders | 1/6 |
| Event | Ramucirumab + Paclitaxel |
|---|---|
| EpistaxisRespiratory, thoracic and mediastinal disorders | 5/6 |
| NeutropeniaBlood and lymphatic system disorders | 4/6 |
| RashSkin and subcutaneous tissue disorders | 4/6 |
| NauseaGastrointestinal disorders | 3/6 |
| PyrexiaGeneral disorders | 3/6 |
| Decreased appetiteMetabolism and nutrition disorders | 3/6 |
| ProteinuriaRenal and urinary disorders | 3/6 |
| AlopeciaSkin and subcutaneous tissue disorders | 3/6 |
| AnaemiaBlood and lymphatic system disorders | 2/6 |
| DiarrhoeaGastrointestinal disorders | 2/6 |
All enrolled participants
| Age, Continuous(years) | Ramucirumab + Paclitaxel |
|---|---|
| Mean | 57.6 ± 15.50 |
| Sex: Female, Male(Participants) | Ramucirumab + Paclitaxel |
|---|---|
| Female | 1 |
| Male | 5 |
| Ethnicity (NIH/OMB)(Participants) | Ramucirumab + Paclitaxel |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 6 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Ramucirumab + Paclitaxel |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 6 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Ramucirumab + Paclitaxel |
|---|---|
| Japan | 6 |
The record gives a start of Nov 2010, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ramucirumab